Iron Sucrose in Patients With Iron Deficiency and POTS

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2021

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Iron-deficiencyPostural Orthostatic Tachycardia Syndrome
Interventions
DRUG

Sucrose

5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted

DRUG

Placebo

Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)

DIAGNOSTIC_TEST

Tilt Table Test

A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04855266 - Iron Sucrose in Patients With Iron Deficiency and POTS | Biotech Hunter | Biotech Hunter